Critical Review: GeoVax Labs (NASDAQ:GOVX) and Biomea Fusion (NASDAQ:BMEA)

GeoVax Labs (NASDAQ:GOVX) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for GeoVax Labs and Biomea Fusion, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	0	0	1	0	3.00
Biomea Fusion	0	2	6	0	2.75

GeoVax Labs presently has a consensus target price of $120.00, indicating a potential upside of 6,917.54%. Biomea Fusion has a consensus target price of $53.13, indicating a potential upside of 309.28%. Given GeoVax Labs’ stronger consensus rating and higher probable upside, equities research analysts clearly believe GeoVax Labs is more favorable than Biomea Fusion.

Profitability

This table compares GeoVax Labs and Biomea Fusion’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-189.16%	-140.10%
Biomea Fusion	N/A	-69.35%	-59.65%

Institutional & Insider Ownership

6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are held by institutional investors. 4.0% of GeoVax Labs shares are held by company insiders. Comparatively, 26.3% of Biomea Fusion shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares GeoVax Labs and Biomea Fusion’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$80,000.00	46.38	-$25.97 million	($13.34)	-0.13
Biomea Fusion	N/A	N/A	-$117.25 million	($3.46)	-3.75

GeoVax Labs has higher revenue and earnings than Biomea Fusion. Biomea Fusion is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

GeoVax Labs has a beta of 2.89, meaning that its stock price is 189% more volatile than the S&P 500. Comparatively, Biomea Fusion has a beta of -0.53, meaning that its stock price is 153% less volatile than the S&P 500.

About GeoVax Labs

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

About Biomea Fusion

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.